Diabetes Drug Might Also Help Treat Heart

New Post Public Reply Private Reply Replies (1) Message Board

Sep 28, 2018 at 12:53 AM 303

Quote:

Diabetes Drug Might Also Help Treat Heart Disease

Researchers say the drug trodusquemine has the potential to reduce arterial fat and perhaps reverse atherosclerosis.

Can an experimental diabetes drug change how we treat heart disease?

In a new study, researchers tout the drug trodusquemine’s ability to “melt away” arterial fat in preclinical trials involving mice.

The research, conducted at the University of Aberdeen in Scotland, is the first of its kind to demonstrate the drug’s ability to reverse atherosclerosis — in some cases with as little as one dose.

“We could show that using the drug chronically, once a week for five weeks or just once toward the end of the study, both resulted in significantly lower atherosclerotic plaque area. It also lowered serum lipids (triglycerides and cholesterol),” Mirela Delibegovic, a study author and a professor in diabetic medicine at the University of Aberdeen, told Healthline.

Mice in the study were treated with either saline (for the control group), a single trodusquemine dose, or multiple doses.

For mice receiving single or multiple doses, there was a decrease in the measured plaque formation while the control group remained unchanged.

The study at Aberdeen is exciting because, in Delibegovic's words, “[The drug] seemed to completely reverse the effects of” atherosclerosis.

Tackling a major killer

https://www.healthline.com/health-news/diabet...-disease#1
Written by Gigen Mammoser on November 21, 2017

Heart disease is the leading cause of death for both men and women in the United States, according to the Centers for Disease Control and Prevention (CDC).

An estimated 610,000 people die per year from heart disease in the United States, accounting for roughly 25 percent of all deaths annually.

Additionally, more than 700,000 Americans will have a heart attack each year.

Atherosclerosis, the narrowing of arteries caused by a buildup of fatty plaque, is a leading cause of heart attack and stroke.

While the condition is present in all people to some degree, it gets worse as you get older.

It can be affected by many lifestyle factors, including diet, activity level, and smoking.

Atherosclerosis slows blood flow to and from the heart, leading to coronary heart disease, angina, and other, more severe, health complications.

Occlusion, the blocking of a blood vessel, can result in serious, sometimes fatal cardiac incidents. Plaque can also dislodge from the blood vessel resulting in a blood clot (thrombosis).

How the drug works

Trodusquemine works by inhibiting PTP1B, an enzyme in the body that has a role in insulin regulation.

Researchers have previously concluded that the drug is effective in correcting obesity-induced insulin resistance, suppressing appetite, and helping with weight loss.

It may also help in treating diabetes — which makes the drug’s potential even more intriguing.

“Cardiovascular disease is the most prevalent cause of mortality in diabetic patients, due to accelerated atherosclerosis. Thus drugs that could improve both the diabetic status and decrease atherosclerotic progression may hold promise for future therapies,” said Delibegovic.

There is also a strong connection between diabetes, heart disease, and atherosclerosis.

Being able to treat obesity, diabetes, and atherosclerosis with one drug would be groundbreaking.

Atherosclerosis is considered a chronic, low-level inflammatory disease, which is accelerated by diabetes.

Prior studies showed that diabetes worsened atherosclerosis. In 2008, a study from the University of Rochester identified the biological mechanisms for why this occurred.

“We have known for a number of years that inhibition of the protein PTP1B should result in positive outcomes on whole-body insulin sensitivity. We have now added to the evidence that it is also positive in regards to atherosclerosis development,” said Delibegovic.

Future research

At this point, trodusquemine is in early clinical trials for the treatment of diabetes and breast cancer.

Further studies will be required to test whether or not the drug’s ability to reverse atherosclerosis is possible in humans.

Delibegovic and her colleagues are looking forward to continuing their research on the drug.

She says they are currently applying for funding to conduct human trials.

“We plan to continue our research moving onto the human setting now that we have the positive preclinical data,” Delibegovic said.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Prix Galien Nominations Spotlight Global Healing

Beyond the Hype: Innovating for Healthier Tomorrows Kicking off in Stockholm on December 1st, the 2026 Prix Galien Bridges Awards isn't just some schmooze-fest; it's a hard-hitting showcase of where true innovation can propel healthcare. Over at the Karolinska Institutet, the Galien Foundation is drawing powerhouses from across the Nordics+ region and showcasing...

Cell Counting Market Growth: USD 17.71 Billion by 2031

The Cell Counting Surge: Money Talks in Science You can't deny it when the numbers speak—a jump from USD 12.39 billion to USD 17.71 billion by 2031 in the cell counting market means something ain't business as usual. That's a robust 7.40% CAGR folks; it's a field being bombarded with innovation. The spark? Automated and advanced cell analysis technology taking the...

TransDigm Surges Ahead with Strong Q4 and FY Results

TransDigm's Impressive Performance in Fiscal 2026 Here's a company that's really kicking it up a notch—TransDigm Group (NYSE:TDG) just reported some solid fourth-quarter numbers that scream growth. Net sales soared to $2,988 million, marking a 23% hike from last year's fourth quarter of $2,437 million. That's a cool $551 million leap, quite the party for shareholders....

Braemar's $358 Million Refinance: A Strategic Shift

Reworking the Debt Load: Braemar's New Move Most days, when a company decides to tinker with its debt, it's like watching paint dry for investors. But with Braemar Hotels & Resorts (NYSE: BHR) announcing a $358 million refinancing package, they're bringing a fresh breath of air to the table. Lemme walk you through why this matters beyond the glossy façade of luxury hotel...

PC Richard & Son Offers Big Black Friday Savings

Holiday Prep Kicks Into High Gear As November ticks on, folks are diving headfirst into the frenzy of holiday planning and spending. What better time for a salvo of sales from P.C. Richard & Son? The appliance stalwart is throwing down the gauntlet with hefty discounts and some intriguing offers on TVs, mattresses, and more. With Black Friday looming, the savvy shopper...

Fake Profiles Dominate Daters' Trust Issues Today

Trust Erosion in the Digital Dating Arena When it comes to modern dating, we're not talking hearts and flowers anymore; it's more like an elaborate game of detective work. A recent survey from Stud or Dud highlights the harsh reality that blind trust in digital dating profiles is about as outdated as sending a singing telegram. Almost half of the respondents pinned fake...

Hi Peach Layne Rides Trend with New Hair Repair Oil

Diving into Beauty Economics with Walmart Now here's a story that ticks every box in the bargain bin playbook—Hi Peach Layne's latest move into the haircare aisle. They're launching a Hair Repair Oil loaded with claims that shout 'value!' loud enough to echo down a Walmart aisle. With a price point of $9.97, it's sliding right into Walmart's "Beauty Finds Under $10"...

Thesis Elements Expands Portfolio with Mappify Buy

Mappify Acquisition: A Smooth Move for Higher Ed Picture a college student trying to juggle classes, work, and life like it's a circus act. That's not too far off from reality, and it's where Thesis America and its new acquisition, Mappify, come into play. By scooping up Mappify, Thesis aims to untangle this scheduling chaos for students across the board. From Data to...

The DOG CATCHER: A New Spin on Pet Waste Cleanup

Revolutionizing the Dreaded Pet Waste Duty Folks, here's a little dose of innovation from the streets of Baltimore: a gadget called the DOG CATCHER. No, it’s not about catching stray dogs, but dealing with their unpleasant leavings. This invention's got a patent pending and all, promising to make the nasty business of dog waste collection a whole lot less disgusting. I...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...